Our mission is to bring life-changing therapeutic benefits to patients living with autoimmune diseases.
A new era of CAR T-cell therapy
Kyverna is pioneering CAR T-cell therapies for autoimmune disease patients by harnessing the power of T cells to achieve a potentially sustained treatment-free remission by resetting the immune system.
Bringing the transformational experience of cell therapies to autoimmune diseases
We believe the success of CAR T-cell therapies in B cell-driven hematological malignancies can be leveraged to deliver therapeutic benefits in patients living with autoimmune diseases.
A patient-centric approach
We are a patient-centered, clinical-stage biopharmaceutical company with active, ongoing clinical trials for multiple autoimmune diseases at different locations across the world.
Therapy
Chimeric antigen receptor (CAR) T-cell therapies
Format
Autologous (KYV-101) and allogeneic
(KYV-201)
Disease Target
B cell-driven autoimmune diseases
Clinical Trials
Lupus nephritis Systemic sclerosis Myasthenia gravis Multiple sclerosis
Clinical trials
Participation in clinical trials is the best way to access our investigational product. Kyverna may consider requests for expanded access when alternative therapy options have been exhausted.